Clinical trials: Finerenone
Heart Failure
Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets
This study should estimate the dose proportionality of BAY94-8862 IR tablets.
- Trial name
- NCT01687920
- Testing
- BAY94-8862 (1.25mg), BAY94-8862 (2.5mg), BAY94-8862 (5mg)
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Primary Aldosteronism
Finerenone for Patients With Primary Aldosteronism (FAIRY)
Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).
- Trial name
- NCT06457074
- Testing
- Finerenone Oral Tablet, Spironolactone Oral Tablet
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Chongqing Medical University
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 2 diabetes (T2D).
- Trial name
- NCT05705271
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 17 sites in India
- Volunteers
- 200 people
- Sponsor
- Bayer
Atrial Fibrillation (AF)
Finerenone After Catheter Ablation to Reduce Atrial Fibrillation Recurrence
Atrial fibrillation (AF) is a common heart rhythm disorder associated with stroke, heart failure, and increased mortality. Catheter ablation with pulmonary vein isolation (PVI) is an effective rhythm-control strategy, but 20-30%…
- Trial name
- FINE-CA (NCT07799519)
- Testing
- Finerenone
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Cheng-Kung University Hospital
Henoch Schönlein Purpura Nephritis
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease.
- Trial name
- FICHSPN (NCT07315191)
- Testing
- ACEI / ARB+finerenone, ACEI/ARB
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Capital Institute of Pediatrics, China
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Albuminuria, Type 2 Diabetes Mellitus (T2DM)
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in…
- Conditions
- Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
- Trial name
- NCT07667517
- Testing
- Finerenone (BAY 94-8862)
- Where
- 13 sites in China
- Volunteers
- 148 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Glomerulonephritis
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.
- Trial name
- NCT06835322
- Testing
- Finerenone
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- DeFineDR (NCT04795726)
- Testing
- Finerenone (BAY94-8862)
- Where
- 11 sites in Bulgaria, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Bayer
HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation)
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
- Trial name
- FINE-VALUE (NCT07575672)
- Testing
- Finerenone
- Where
- 61 sites in China
- Volunteers
- 2,832 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Kidney Transplant; Complications
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs).
- Trial name
- NCT06059664
- Testing
- Finerenone Oral Tablet
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Cardiovascular Autonomic Neuropathy, Type 2 Diabetes
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
Diabetic neuropathy is a serious and common complication of diabetes that currently has no cure. One form of this condition is cardiovascular autonomic neuropathy (CAN), which affects about 20% of people with diabetes-an…
- Conditions
- Cardiovascular Autonomic Neuropathy, Type 2 Diabetes, Diabetic Neuropathies
- Trial name
- FibroCAN (NCT06906081)
- Testing
- Kerendia (Finerenone, BAY94-8862)
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Peter Rossing
Hypertension (HTN)
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
- Trial name
- NEPHRON (NCT07223502)
- Testing
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis
This is a single-center prospective observational clinical study conducted at the First Affiliated Hospital of Chongqing Medical University.
- Trial name
- NCT07717697
- Testing
- Finerenone
- Volunteers
- 425 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice
This is an observational study in which data from people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who have already started or will start CKD or T2D treatment are collected and studied.
- Trial name
- FINEGUST (NCT05526157)
- Testing
- Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Diabetic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when…
- Trial name
- FIGARO-DKD (NCT02545049)
- Testing
- Finerenone (BAY94-8862)
- Where
- 975 sites in United States, Argentina and 46 more
- Volunteers
- 7,352 people
- Sponsor
- Bayer
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to…
- Trial name
- CONFIDENCE (NCT05254002)
- Testing
- Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Finerenone (BAY94-8862 ) 20 mg
- Where
- 173 sites in United States, Belgium and 12 more
- Volunteers
- 1,664 people
- Sponsor
- Bayer
Hypertension (HTN)
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg/day) with…
- Trial name
- NCT07678151
- Testing
- Empagliflozin and Finerenone
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- Heart Health Research Center
Chronic Kidney Diseases
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
- Trial name
- CAPTIVATE (NCT06058585)
- Testing
- Finerenone, Semaglutide
- Where
- 51 sites in Australia, India and 3 more
- Volunteers
- 2,000 people
- Sponsor
- The George Institute
Acute Heart Failure
Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who…
- Trial name
- FACILITATE-HF (NCT07397650)
- Testing
- Finerenone Oral Tablet
- Where
- 21 sites in Japan
- Volunteers
- 550 people
- Sponsor
- Juntendo University